Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids

van Tilborg,A. A.G.; Sweep,F. C.G.J.; Geurts-Moespot,A. J.; Wetzels,A. M.M.; de Waal,R. M.W.; Westphal,J. R.; Massuger,L. F.A.G.

doi:10.3892/ijo.2014.2303

Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids

Authors:
- A. A.G. van Tilborg
- F. C.G.J. Sweep
- A. J. Geurts-Moespot
- A. M.M. Wetzels
- R. M.W. de Waal
- J. R. Westphal
- L. F.A.G. Massuger
View Affiliations

Affiliations: Department of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
Published online on: February 14, 2014 https://doi.org/10.3892/ijo.2014.2303
Pages: 1394-1400

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In many tumor types, angiogenesis is the net result of pro- and anti-angiogenic mediators and correlated with metabolic activity, growth, and degree of malignancy. One of the first discovered anti-angiogenic compounds is angiostatin, a proteolytic fragment of plasminogen. The requirements for in vivo angiostatin generation have not yet been determined. We investigated the levels of plasminogen and angiostatin by western blotting and of components of the plasminogen activator complex by ELISA in cyst fluid derived from benign and malignant ovarian tumors. Fluid samples from functional ovarian follicles, dermoid cysts and endometriotic lesions were evaluated separately. When no or minimal amounts of plasminogen were present in the cyst fluids, angiostatin was generally absent as well, irrespective of plasminogen activator concentrations. When plasminogen was present, the degree of conversion of plasminogen to angiostatin was significantly correlated with the level of uPA, and, to a lesser extent, to the tPA level. However, angiostatin was also found in a number of cyst fluid samples with minimal or no plasminogen activators, suggesting the involvement of other angiostatin generating proteases in these samples. Conversely, no angiostatin was observed in a number of cyst fluid samples containing both plasminogen and plasminogen activators. The presence of an inhibitor of the enzymatic activity of uPA and/or tPA, like PAI-1, may explain this finding. Our data show that plasminogen activators are clearly involved in in vivo angiostatin formation in ovarian cysts. Most likely, however, other proteases, as well as inhibitors of plasminogen activators, are involved as well.

View Figures

View References

1.	Folkman J: Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 333:1757–1763. 1995. View Article : Google Scholar : PubMed/NCBI
2.	Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995. View Article : Google Scholar : PubMed/NCBI
3.	Carmeliet P and Collen D: Molecular analysis of blood vessel formation and disease. Am J Physiol. 273:H2091–H2104. 1997.PubMed/NCBI
4.	Iruela-Arispe ML and Dvorak HF: Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb Haemost. 78:672–677. 1997.PubMed/NCBI
5.	Talks KL and Harris AL: Current status of antiangiogenic factors. Br J Haematol. 109:477–489. 2000. View Article : Google Scholar
6.	Bicknell R and Harris AL: Mechanisms and therapeutic implications of angiogenesis. Curr Opin Oncol. 8:60–65. 1996. View Article : Google Scholar : PubMed/NCBI
7.	Liekens S, De Clercq E and Neyts J: Angiogenesis: regulators and clinical applications. Biochem Pharmacol. 61:253–270. 2001. View Article : Google Scholar : PubMed/NCBI
8.	Hofmann UB, Westphal JR, Van Muijen GN and Ruiter DJ: Matrix metalloproteinases in human melanoma. J Invest Dermatol. 115:337–344. 2000. View Article : Google Scholar : PubMed/NCBI
9.	Pozzi A, Moberg PE, Miles LA, Wagner S, Soloway P and Gardner HA: Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci USA. 97:2202–2207. 2000. View Article : Google Scholar : PubMed/NCBI
10.	Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA and Cheresh DA: Definition of two angiogenic pathways by distinct alpha v integrins. Science. 270:1500–1502. 1995. View Article : Google Scholar : PubMed/NCBI
11.	Brooks PC, Clark RA and Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 264:569–571. 1994. View Article : Google Scholar : PubMed/NCBI
12.	O’Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:315–328. 1994.
13.	O’Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:277–285. 1997.
14.	Holmgren L, O’Reilly MS and Folkman J: Dormancy of micro-metastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1:149–153. 1995. View Article : Google Scholar : PubMed/NCBI
15.	O’Reilly MS, Holmgren L, Chen C and Folkman J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 2:689–692. 1996.PubMed/NCBI
16.	Gately S, Twardowski P, Stack MS, et al: The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA. 94:10868–10872. 1997. View Article : Google Scholar : PubMed/NCBI
17.	Westphal JR, Van’t Hullenaar R, Geurts-Moespot A, et al: Angiostatin generation by human tumor cell lines: involvement of plasminogen activators. Int J Cancer. 86:760–767. 2000. View Article : Google Scholar : PubMed/NCBI
18.	Cornelius LA, Nehring LC, Harding E, et al: Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol. 161:6845–6852. 1998.PubMed/NCBI
19.	Dong Z, Kumar R, Yang X and Fidler IJ: Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell. 88:801–810. 1997. View Article : Google Scholar : PubMed/NCBI
20.	Heidtmann HH, Nettelbeck DM, Mingels A, Jager R, Welker HG and Kontermann RE: Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer. 81:1269–1273. 1999. View Article : Google Scholar : PubMed/NCBI
21.	Puzer L, Barros NM, Paschoalin T, et al: Cathepsin V, but not cathepsins L, B and K, may release angiostatin-like fragments from plasminogen. Biol Chem. 389:195–200. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Soff GA: Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev. 19:97–107. 2000. View Article : Google Scholar : PubMed/NCBI
23.	Rotenberg RG, Rozas NS, Guerri L, et al: Elevated levels of angiostatin in effusions from patients with malignant disease. Oncol Rep. 11:523–528. 2004.PubMed/NCBI
24.	Grebenschikov N, Geurts-Moespot A, De Witte H, et al: A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. Int J Biol Markers. 12:6–14. 1997.PubMed/NCBI
25.	Span PN, Grebenchtchikov N, Geurts-Moespot J, Westphal JR, Lucassen AM and Sweep CG: EORTC Receptor and Biomarker Study Group Report: a sandwich enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and tumor tissue extracts. Int J Biol Markers. 15:184–191. 2000.
26.	Murthi P, Barker G, Nowell CJ, et al: Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression. Gynecol Oncol. 92:80–88. 2004. View Article : Google Scholar
27.	Drenberg CD, Saunders BO, Wilbanks GD, et al: Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer. Gynecol Oncol. 117:117–124. 2010. View Article : Google Scholar : PubMed/NCBI
28.	de Witte JH, Sweep CG, Klijn JG, et al: Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. Br J Cancer. 80:286–294. 1999.PubMed/NCBI
29.	de Witte JH, Sweep CG, Klijn JG, et al: Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. Br J Cancer. 79:1190–1198. 1999.PubMed/NCBI
30.	Look MP, van Putten WL, Duffy MJ, et al: Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 94:116–128. 2002. View Article : Google Scholar : PubMed/NCBI
31.	Manders P, Tjan-Heijnen VC, Span PN, et al: Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer. Cancer Res. 64:659–664. 2004. View Article : Google Scholar
32.	Manders P, Tjan-Heijnen VC, Span PN, et al: The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer. Thromb Haemost. 91:514–521. 2004.
33.	de Groot-Besseling RR, Ruers TJ, Lamers-Elemans IL, Maass CN, de Waal RM and Westphal JR: Angiostatin generating capacity and anti-tumour effects of D-penicillamine and plasminogen activators. BMC Cancer. 6:1492006.PubMed/NCBI
34.	de Groot-Besseling RR, Ruers TJ, van Kraats AA, et al: Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model. Int J Cancer. 112:329–334. 2004.